Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

pharmaceutical industry
José Baselga, Renowned Oncologist, Dies at 61
José Baselga, Renowned Oncologist, Dies at 61
Asher Jones | Mar 22, 2021
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
Biopharma Looks to the Netherlands as European Hub
Biopharma Looks to the Netherlands as European Hub
Jef Akst | Feb 1, 2021
The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.
Pharma Looks to Outer Space to Boost Drug R&D
Pharma Looks to Outer Space to Boost Drug R&D
Katarina Zimmer | Dec 1, 2020
There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Thousands of Coronavirus Infections Stemmed from a Biotech Event
Thousands of Coronavirus Infections Stemmed from a Biotech Event
Amanda Heidt | Aug 26, 2020
Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.
Gilead Urged to Explore Remdesivir Relative as COVID-19 Drug
Gilead Urged to Explore Remdesivir Relative as COVID-19 Drug
Catherine Offord | Aug 11, 2020
Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
How the Pharma Industry Pulled Off the Pivot to COVID-19
How the Pharma Industry Pulled Off the Pivot to COVID-19
Diana Kwon | Jul 13, 2020
The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Pharma’s Ghost Labs Find New Life
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Immune Cell Bank Bets on Future CAR T Success
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
Chemist Behind the Combined Oral Contraceptive Dies at 102
Chemist Behind the Combined Oral Contraceptive Dies at 102
Catherine Offord | Jul 2, 2019
George Rosenkranz was part of a team in Mexico City that first synthesized norethindrone in 1951.

Miracle Elixirs
Miracle Elixirs
Bob Grant | Apr 1, 2019
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
Opinion: The “Money Culture” in Academic Biomedical Research
Opinion: The “Money Culture” in Academic Biomedical Research
David Rubenson | Mar 29, 2019
A drive for revenue is damaging basic science.
Esketamine, a Treatment for Depression, Receives FDA Approval
Esketamine, a Treatment for Depression, Receives FDA Approval
Carolyn Wilke | Mar 6, 2019
The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.